111, Inc. (YI) Stock Analysis

Company Overview

111, Inc. operates an integrated online and offline platform within the healthcare market of the People's Republic of China, serving customers through distinct B2C and B2B segments. This operational structure focuses on supply chain integration services that assist pharmaceutical companies in managing product distribution. The company is classified within the Healthcare sector and the Medical Distribution industry, positioning it as a specialized intermediary in the complex pharmaceutical supply chain. In terms of scale, 111, Inc. carries a market capitalization of $54.05M and reports annual revenue of $13.58B while employing 1238 individuals. These figures indicate a significant operational footprint that contrasts sharply with its market cap, suggesting that the company's valuation does not currently reflect its substantial revenue generation or the breadth of its distribution network.

Financial Health

The company reports revenue of $13.58B for the trailing twelve months, yet this revenue base is associated with a net income of $-70,012,000 and an EBITDA of $3.98M. The substantial gap between the high revenue figure and the negative net income reveals a highly leveraged cost structure where operating expenses and costs of goods sold consume nearly all generated revenue, leaving minimal profitability. Free cash flow stands at $-22,583,250, which indicates that the company is consuming cash reserves rather than generating liquidity from its core operations. This negative free cash flow limits the company's financial flexibility, as it must rely on existing cash balances or external financing to cover operational burn. Three distinct margin metrics highlight the operational challenges: the gross margin is 2.8%, the operating margin is -0.1%, and the profit margin is -0.5%. These margin levels indicate that the company operates with razor-thin gross profits and is currently posting losses at both the operating and net income levels. On the balance sheet, the company holds $493.62M in cash against $204.73M in debt, resulting in a debt-to-equity ratio of 93.56. Despite the high leverage indicated by the debt-to-equity ratio, the cash position appears sufficient to cover short-term obligations, though the negative cash flow dynamic is concerning. The current ratio is 1.07, which suggests that the company's current assets are only slightly higher than its current liabilities, indicating a tight but technically sufficient short-term liquidity position. Finally, the return on equity is -10.9% and the return on assets is -0.2%, metrics that reveal management is currently destroying value rather than generating returns on the capital invested in the business.

Valuation Assessment

The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to the lack of earnings, while the Forward P/E is 44.54. The existence of a forward P/E without a trailing P/E implies that the market is pricing in a complete turnaround in earnings trajectory, expecting the company to become profitable in the future despite current losses. The price-to-book ratio is -0.55, which indicates that the market is valuing the company at less than its book value and reflects a significant discount, likely due to the negative equity position. The price-to-sales ratio is 0.00, suggesting that traditional sales-based valuation multiples are not applicable given the negative earnings, while the EV/EBITDA stands at 426.96, a multiple that is exceptionally high and implies a significant premium relative to current cash flows or a speculative valuation based on future expectations. The stock has a 52-Week High of $11.17 and a 52-Week Low of $2.48, indicating a wide trading range of $8.69. Without a specific current share price provided in the available facts, the relative positioning within this range cannot be calculated, but the wide range itself suggests high volatility and sensitivity to market sentiment regarding the company's turnaround prospects. The beta value is 0.64, which means the stock price is expected to be less volatile than the broader market, moving 36% less than the market index on average during periods of fluctuation.

Growth & Income

Revenue growth year-over-year is -16.7%, while earnings growth is listed as N/A due to the absence of positive earnings data. The contraction in revenue indicates a decline in business volume or pricing power, and since earnings are already negative, the relationship between revenue and earnings growth is not applicable in a traditional sense where one drives the other positively. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividends means the company is not distributing cash to shareholders and is instead retaining capital, although the negative free cash flow suggests there is little excess cash available to reinvest. Consequently, the company reinvests earnings into growth, but given the negative free cash flow and negative net income, this reinvestment is effectively funded by cash reserves or debt rather than operational profits. The overall growth and income profile is characterized by negative revenue expansion, a lack of current profitability, and no income distribution to shareholders, presenting a high-risk scenario for investors seeking capital appreciation or income.